Susana Lisboa

Susana Lisboa

Auto-generated profile, based on publicly available information

Susana Lisboa

Department of Genetics, Portuguese Oncology Institute, and Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Blood
Verified
Journal Article
Closed access
PDF file
KGKonstantinos Georgiou
Konstantinos Georgiou
LCLongyun Chen
Longyun Chen
MBMattias Berglund
Mattias Berglund
WRWeicheng Ren
Weicheng Ren
Noel de MirandaNoel de Miranda
Noel de Miranda
QPQiang Pan-Hammarström
Qiang Pan-Hammarström
Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive types of B-cell lymphoma. Deregulation of proto-oncogene expression following a translocation, most notably to the immunoglobulin heavy chain locus (IGH), is one of the hallmarks of DLBCL. By whole genome sequencing analysis, we have identified the PD-L1/PD-L2 locus as a recurrent translocation partner for IGH in DLBCL. PIM1 and TP63 were also identified as novel translocation partners for PD-L1/PD-L2. Fluorescence in situ hybridization was furthermore used to rapidly screen an expanded DLBCL cohort. Collectively, a subset of samples was found to be affected by gains (12%), amplifications (3%) and translocations (4%) of the PD-L1/PD-L2 locus. RNA sequencing data coupled with immunohistochemistry revealed that these cytogenetic alterations correlated with increased expression of PD-L1 but not of PD-L2. Moreover, cytogenetic alterations affecting the PD-L1/PD-L2 locus were more frequently observed in the non-germinal center B-cell like (non-GCB) subtype of DLBCL. These findings demonstrate the genetic basis of PD-L1 overexpression in DLBCL and suggest that treatments targeting the PD-1–PD-L1/PD-L2 axis might benefit DLBCL patients, especially those belonging to the more aggressive non-GCB subtype.

16 October 2014 in Blood
Verified
Journal Article
Open access
PDF file
Noel de MirandaNoel de Miranda
Noel de Miranda
KGKonstantinos Georgiou
Konstantinos Georgiou
LCLongyun Chen
Longyun Chen
CWChenglin Wu
Chenglin Wu
ZGZhibo Gao
Zhibo Gao
QPQiang Pan-Hammarström
Qiang Pan-Hammarström
Key Points: Sequencing of Chinese DLBCL reveals novel mutation targets and highlights additional/alternative tumorigenic pathways in these tumors. DTX1 is frequently mutated in Chinese DLBCL and deleterious mutations in this gene contribute to the activation of the Notch pathway.

19 August 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
Noel de MirandaNoel de Miranda
Noel de Miranda
RPRoujun Peng
Roujun Peng
KGKonstantinos Georgiou
Konstantinos Georgiou
CWChenglin Wu
Chenglin Wu
ESElin Falk Sörqvist
Elin Falk Sörqvist
QPQiang Pan-Hammarström
Qiang Pan-Hammarström
DNA repair mechanisms are fundamental for B cell development, which relies on the somatic diversification of the immunoglobulin genes by V(D)J recombination, somatic hypermutation, and class switch recombination. Their failure is postulated to promote genomic instability and malignant transformation in B cells. By performing targeted sequencing of 73 key DNA repair genes in 29 B cell lymphoma samples, somatic and germline mutations were identified in various DNA repair pathways, mainly in diffuse large B cell lymphomas (DLBCLs). Mutations in mismatch repair genes (EXO1, MSH2, and MSH6) were associated with microsatellite instability, increased number of somatic insertions/deletions, and altered mutation signatures in tumors. Somatic mutations in nonhomologous end-joining (NHEJ) genes (DCLRE1C/ARTEMIS, PRKDC/DNA-PKcs, XRCC5/KU80, and XRCC6/KU70) were identified in four DLBCL tumors and cytogenetic analyses revealed that translocations involving the immunoglobulin-heavy chain locus occurred exclusively in NHEJ-mutated samples. The novel mutation targets, CHEK2 and PARP1, were further screened in expanded DLBCL cohorts, and somatic as well as novel and rare germline mutations were identified in 8 and 5% of analyzed tumors, respectively. By correlating defects in a subset of DNA damage response and repair genes with genomic instability events in tumors, we propose that these genes play a role in DLBCL lymphomagenesis.

8 May 2006 in Oncogene
Verified
Journal Article
Closed access
NCN Cerveira
N Cerveira
CCCecília Correia
Cecília Correia
SBS Bizarro
S Bizarro
CPC Pinto
C Pinto
SLS Lisboa
S Lisboa
MTManuel R. Teixeira
Manuel R. Teixeira

11 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJoao Ramalho-Carvalho
Joao Ramalho-Carvalho
MPMalini Pires
Malini Pires
SLSusana Lisboa
Susana Lisboa
IGInês Graça
Inês Graça
PRPatrícia Rocha
Patrícia Rocha
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
MGMT downregulation in high-grade gliomas (HGG) has been mostly attributed to aberrant promoter methylation and is associated with increased sensitivity to alkylating agent-based chemotherapy. However, HGG harboring 10q deletions also benefit from treatment with alkylating agents. Because the MGMT gene is mapped at 10q26, we hypothesized that both epigenetic and genetic alterations might affect its expression and predict response to chemotherapy. To test this hypothesis, promoter methylation and mRNA levels of MGMT were determined by quantitative methylation-specific PCR (qMSP) or methylation-specific multiplex ligation dependent probe amplification (MS-MLPA) and quantitative RT-PCR, respectively, in a retrospective series of 61 HGG. MGMT/chromosome 10 copy number variations were determined by FISH or MS-MLPA analysis. Molecular findings were correlated with clinical parameters to assess their predictive value. Overall, MGMT methylation ratios assessed by qMSP and MS-MLPA were inversely correlated with mRNA expression levels (best coefficient value obtained with MS-MLPA). By FISH analysis in 68.3% of the cases there was loss of 10q26.1 and in 15% of the cases polysomy was demonstrated; the latter displayed the highest levels of transcript. When genetic and epigenetic data were combined, cases with MGMT promoter methylation and MGMT loss depicted the lowest transcript levels, although an impact in response to alkylating agent chemotherapy was not apparent. Cooperation between epigenetic (promoter methylation) and genetic (monosomy, locus deletion) changes affecting MGMT in HGG is required for effective MGMT silencing. Hence, evaluation of copy number alterations might add relevant prognostic and predictive information concerning response to alkylating agent-based chemotherapy.

15 August 2003
Verified
Journal Article
Closed access
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
ICIsabel Costa
Isabel Costa
MMM Conceição Martins
M Conceição Martins
PMPaula Monteiro
Paula Monteiro
SLSusana Lisboa
Susana Lisboa
CLCarlos Lopes
Carlos Lopes